Research leads evaluating computational tools often ask what the workflow looks like from start to finish. Not the architecture diagram, but the human experience: when the scientist sits down, what they do, what they receive, and how long it takes.
Here is a concrete example. A small-molecule drug discovery team is studying a kinase target. They have a lead scaffold with three known inhibitors that bind reasonably well and want to test whether substituent changes at two scaffold positions improve or weaken binding. It is Tuesday afternoon. Their weekly group meeting is Wednesday morning at 9 AM.
2:30 PM: The hypothesis
The medicinal chemist has drawn six new compounds in ChemDraw. Each uses the same core scaffold, with two R-group changes at position 3, a methyl-substituted pyridine or trifluoromethyl pyrimidine, and three changes at position 6, H, F, or a small morpholine ring. The question is whether any improve on the current best compound, a chloro-substituted analog with a measured IC50 of 340 nM in the kinase assay.
The simulation agent receives the SMILES for the six compounds, the target kinase identifier, and a request for docking scores relative to the reference compound. The preferred protein structure is identified by PDB accession number. The team selected it in a previous run. Submission takes about eight minutes.
2:38 PM: What the agent does
The agent converts the SMILES inputs into 3D conformers and assigns protonation states at pH 7.4. It retrieves the specified PDB structure, removes solvent, adds hydrogens, and centers the docking grid on the co-crystallized inhibitor in the reference structure. It then performs flexible ligand docking for the six compounds and reference compound using a standard kinase-optimized scoring protocol.
Compute time for this target and compound set is about four hours. Work is distributed across multiple cores, reducing wall-clock time versus serial computation. The agent also applies a basic ADMET filter, flagging predicted hERG binding concern or high metabolic instability, as requested in the team's protocol preferences.
6:45 PM: The results email arrives
The medicinal chemist receives the results before leaving. The structured output has three parts: a ranked table of the six compounds plus the reference, ordered by docking score with the reference for calibration; a binding pose image for each compound, with key hydrogen bond contacts labeled; and an ADMET summary. Two of the six compounds have a predicted hERG concern at the alert threshold, and one has a metabolic instability flag.
Two of the six compounds score meaningfully better than the reference. The trifluoromethyl-pyrimidine at position 3 combined with fluorine at position 6 gives the highest docking score, and its pose shows a new contact between the trifluoromethyl group and a hydrophobic pocket in the kinase hinge region. The morpholine-substituted compound at position 6 scores similarly well but has the hERG flag.
8:30 PM: A quick check
The chemist reviews the pose visualizations for fifteen minutes, checking the two high-scoring compounds. The predicted hinge-region interaction looks plausible, and the fluoropyrimidine orientation matches similar groups in published co-crystal structures of this kinase class. The morpholine pose is also reasonable, but its ADMET flag is a real concern at this project stage.
The meeting note recommends synthesizing the fluoropyrimidine variant first. The morpholine is interesting for binding but should be assessed against the hERG concern before synthesis resources are committed. The four other compounds are deprioritized by docking score, although the H-substituted position-6 variant may be retained as a control.
9:00 AM Wednesday: The group meeting
The team has a concrete basis for discussion: a specific candidate with a rationalized binding hypothesis, rather than a scaffold decision based on chemical intuition alone. The trifluoromethyl group should occupy a defined hydrophobic pocket, the fluorine at position 6 should improve metabolic stability versus the unsubstituted analog, and the docking improvement over the reference supports experimental follow-up.
The decision is to synthesize the fluoropyrimidine compound. The morpholine goes on a watch list until hERG assay data returns for the reference compound series. The kinase IC50 assay is scheduled for the new compound two weeks out, consistent with the synthesis timeline.
What this example shows, and what it does not
This 12-hour cycle works because the target and inputs were prepared in advance. The team had validated its preferred protein structure, had a reference compound with measured activity for calibration, and asked a focused question: six variants on a known scaffold, not broad chemical-space exploration.
For a new target without prior computational setup, the first run takes longer. Receptor preparation requires choices about the structure, binding-site validation, and ADMET preferences. Those choices are made once, and later runs on that target reuse the setup. The 12-hour cycle describes steady-state use, not the first run.
This run did not replace synthesis or assay work. It changed what gets synthesized: one candidate with a rationalized binding hypothesis instead of six compounds selected by chemical intuition. Whether binding improves remains an experimental question. The in-silico step makes that question more focused and the synthesis investment more targeted.
